The Lilly MDR-TB Partnership was created in 2003 to address the challenge of multidrug-resistant tuberculosis (MDR-TB). The Partnership is a public-private initiative of the pharmaceutical company, Eli Lilly and Company. It mobilizes over 20 partners on five continents to battle MDR-TB. This public/private initiative offers education, training, and improved care to people worldwide who have fallen victim to deadly multidrug-resistant TB. Working in more than 80 nations, The Lilly MDR-TB Partnership has trained doctors and nurses to recognize, treat, monitor, and prevent the spread of multidrug-resistant TB. These healthcare professionals have raised awareness to reduce the stigma of the disease, promoted prevention, researched drugs to improve treatment, and advocated for some of the world’s most vulnerable populations. The partnership is working part of an overall effort to meet the target: treating a cumulative 800,000 MDR-TB patients by 2015.
|Value||USD 135 Million|